<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507687</url>
  </required_header>
  <id_info>
    <org_study_id>192024-093</org_study_id>
    <secondary_id>2015-002131-18</secondary_id>
    <nct_id>NCT02507687</nct_id>
  </id_info>
  <brief_title>Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost&#xD;
      SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or&#xD;
      ocular hypertension who are not adequately managed with topical IOP-lowering medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 27, 2015</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in IOP at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in IOP at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Intraocular Pressure (IOP) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP change from baseline at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP change from baseline at Week 15</measure>
    <time_frame>Baseline, Week 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP change from baseline at Week 20</measure>
    <time_frame>Baseline, Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator</measure>
    <time_frame>Baseline, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of SLT eyes achieving ≥ 20% reduction at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of SLT eyes achieving ≥ 20% reduction at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of SLT eyes achieving ≥ 20% reduction at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Bimatoprost Sustained-Release (SR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost SR</intervention_name>
    <description>Up to two Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).</description>
    <arm_group_label>Bimatoprost Sustained-Release (SR)</arm_group_label>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Bimatoprost SR</intervention_name>
    <description>Up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).</description>
    <arm_group_label>Bimatoprost Sustained-Release (SR)</arm_group_label>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective Laser Trabeculoplasty</intervention_name>
    <description>Selective Laser Trabeculoplasty administered on Day 1.</description>
    <arm_group_label>Bimatoprost Sustained-Release (SR)</arm_group_label>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Selective Laser Trabeculoplasty</intervention_name>
    <description>Sham Selective Laser Trabeculoplasty administered on Day 1.</description>
    <arm_group_label>Bimatoprost Sustained-Release (SR)</arm_group_label>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that&#xD;
             require IOP lowering treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eye surgery (including cataract surgery) and or eye laser surgery within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Previous use of commercially available Bimatoprost SR; c oncurrent enrollment in&#xD;
             another Allergan Bimatoprost SR study; or previous enrollment in which an implant was&#xD;
             received.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trinity Research Group /ID# 234598</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Advanced Eye Research Institute /ID# 234947</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M&amp;M Eye Institute /ID# 235391</name>
      <address>
        <city>Prescott</city>
        <state>Arizona</state>
        <zip>86301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walman Eye Center /ID# 236054</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Center for Clin Res /ID# 237412</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Ophthalmology /ID# 235995</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Speciality Eye Care Medical Group /ID# 236001</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute /ID# 237042</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeside Vision Center /ID# 234971</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical Group Inc. /ID# 235999</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Eye Associates /ID# 235326</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates /ID# 235166</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Drug Trials Inc. /ID# 235169</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates Inc. /ID# 235021</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida /ID# 236876</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Eye PA /ID# 235431</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Andrew Gardner Logan, FL /ID# 236946</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 237737</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research, LLC /ID# 236678</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260-4180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago Illinois Eye and Ear Infirmary /ID# 234875</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sabates Eye Centers /ID# 234868</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute- Edgewood /ID# 236714</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017-3415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute /ID# 236690</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206-1738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Glaucoma Specialists /ID# 234799</name>
      <address>
        <city>Reading</city>
        <state>Massachusetts</state>
        <zip>01867</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Eye Center /ID# 235791</name>
      <address>
        <city>Fraser</city>
        <state>Michigan</state>
        <zip>48026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Vision Research Foundation at Pepose Vision Institute /ID# 235879</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellish Vision Institute /ID# 236064</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Eye Institute PA /ID# 234944</name>
      <address>
        <city>South Orange</city>
        <state>New Jersey</state>
        <zip>07079-1855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of New Mexico /ID# 235115</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albemarle Clinical Trials LLC /ID# 235144</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagan Strinden Vision /ID# 234898</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Eye Surgeons /ID# 235848</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and Christie and Associates /ID# 234594</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists /ID# 235129</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Eye Group P.C. /ID# 236114</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601-2644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital /ID# 236487</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Centers for Sight,PC /ID# 237017</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Eye Center /ID# 236116</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Eye Center /ID# 235632</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Institute /ID# 235977</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center /ID# 234533</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Eye Institute /ID# 235174</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queensland Eye Institute /ID# 236074</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgery Associates /ID# 235872</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Eye Specialists /ID# 234614</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>VIC3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waverley Eye Clinic /ID# 234997</name>
      <address>
        <city>Glen Waverley</city>
        <state>Victoria</state>
        <zip>3150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lions Eye Institute /ID# 236832</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essendon Eye Clinic /ID# 235433</name>
      <address>
        <city>Essendon</city>
        <zip>3040</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Eye Clinic /ID# 236118</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Eye Institute /ID# 236003</name>
      <address>
        <city>Melbourne</city>
        <zip>3058</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Clinic Bellevue /ID# 234631</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup /ID# 237709</name>
      <address>
        <city>Glostrup</city>
        <state>Hovedstaden</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de la Baie /ID# 235842</name>
      <address>
        <city>Avranches</city>
        <zip>50300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hopital Pellegrin /ID# 237705</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Honore Cave - Pharmacie /ID# 235925</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hospital Pasteur 2 /ID# 235844</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Hopital Civil /ID# 237837</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse Purpan - Hopital Pierre Paul Riquet /ID# 235841</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 235966</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Magdeburg /ID# 237284</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 237211</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 237741</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center /ID# 236757</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center /ID# 235742</name>
      <address>
        <city>Naharia</city>
        <zip>2210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 237698</name>
      <address>
        <city>Petakh Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye Hospital /ID# 235253</name>
      <address>
        <city>Remuera</city>
        <state>Auckland</state>
        <zip>1050</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Eye Specialists /ID# 236081</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8013</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Eye Specialists /ID# 236111</name>
      <address>
        <city>Wellington</city>
        <zip>6011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Eye Institute /ID# 235092</name>
      <address>
        <city>Makati City</city>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peregrine Eye and Laser Institute /ID# 236220</name>
      <address>
        <city>Makati City</city>
        <zip>1209</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Santos Medical Center /ID# 235325</name>
      <address>
        <city>San Juan City</city>
        <zip>1502</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyki i Mikrochirurgii Oka - LENS dr n. med. Slawomir Zalewski /ID# 235929</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-424</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical ophthalmology hospital n.a. V.P. Vihodtsev. /ID# 236041</name>
      <address>
        <city>Omsk</city>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University /ID# 236997</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Derby and Burton NHS Foundation Trust /ID# 237129</name>
      <address>
        <city>Derby</city>
        <state>Derbyshire</state>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary's Hospital /ID# 234899</name>
      <address>
        <city>Greater London</city>
        <state>Kent</state>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust /ID# 236806</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epsom &amp; St Helier University Hospital NHS Trust /ID# 236902</name>
      <address>
        <city>Carshalton</city>
        <state>Surrey</state>
        <zip>SM5 1AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust /ID# 238315</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian /ID# 237450</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust /ID# 234777</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust /ID# 237318</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Estonia</country>
  </removed_countries>
  <link>
    <url>http://allerganclinicaltrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@allergan.com for assistance.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

